Generic competition · all medicines · read 12 November 2026
Is there a generic of Losartan Potassium, and who makes it?
Losartan Potassium appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 16 generic makers listed as marketed across them. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came 15 years after the first brand approval. This is the Orange Book's listing, not a forecast.
Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.
- Losartan Potassium appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 16 generic makers listed as marketed across them.
- 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
- Where both are dated, the first generic approval came 15 years after the first brand approval.
- Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.
Tablet, Oral
Four or more generic makers listed
Brand listed as marketed: Cozaar. 16 generic makers with 48 generic products listed as marketed; the first generic approval is dated 6 April 2010.
| Generic maker (applicant) | First approval | Products |
|---|---|---|
| Aiping Pharmaceutical Inc | 6 October 2010 | 3 |
| Alembic Pharmaceuticals Ltd | 6 October 2010 | 3 |
| Aurobindo Pharma Ltd | 6 October 2010 | 3 |
| Chartwell Rx Sciences Llc | 6 October 2010 | 3 |
| Lupin Ltd | 6 October 2010 | 3 |
| Strides Pharma Global Pte Ltd | 6 October 2010 | 3 |
| Watson Laboratories Inc | 6 October 2010 | 3 |
| Zydus Pharmaceuticals Usa Inc | 6 October 2010 | 3 |
| Prinston Pharmaceutical Inc | 6 June 2011 | 3 |
| Macleods Pharmaceuticals Ltd | 30 May 2012 | 3 |
| Jubilant Cadista Pharmaceuticals Inc | 18 September 2012 | 3 |
| Hetero Labs Ltd Unit V | 12 August 2015 | 3 |
4 more makers are listed in the data.
Patents and exclusivities still listed
No unexpired patent or exclusivity is listed against the marketed brand products in this group.
Suspension, Oral
Brand listed, no generic listed as marketed
Brand listed as marketed: Arbli. No generic is listed as marketed.
Patents and exclusivities still listed
- 7 October 2041Patent 12156869 drug product
- 7 October 2041Patent 12605365 drug product
- 7 October 2041Patent 11890273 drug product
US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.
Where can you go from this result?
Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.